Carmen Nóbrega

Prof. Dr. Carmen Nóbrega

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2011 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
MOMaria Manuel Oliveira
Maria Manuel Oliveira
JTJosé Teixeira
José Teixeira
CNCarmen Nóbrega
Carmen Nóbrega
Luís Manuel Lourenço FélixLuís Manuel Lourenço Félix
Luís Manuel Lourenço Félix
VSVilma Sardão
Vilma Sardão
Francisco PeixotoFrancisco Peixoto
Francisco Peixoto

23 February 2020 in Transboundary and Emerging Diseases
Verified
Journal Article
Closed access
PDF file
JMJoão Mesquita
João Mesquita
NSNanci Santos-Ferreira
Nanci Santos-Ferreira
AFAna S. Ferreira
Ana S. Ferreira
CACarlos Manuel de Sousa Albuquerque Albuquerque
Carlos Manuel de Sousa Albuquerque Albuquerque
CNCarmen Nóbrega
Carmen Nóbrega
MNMaria S. J. Nascimento
Maria S. J. Nascimento

1 October 2013 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
CNCarmen Nóbrega
Carmen Nóbrega
RPRosário Lima Viseu de Carvalho Pinto-Leite
Rosário Lima Viseu de Carvalho Pinto-Leite
RARegina Arantes-Rodrigues
Regina Arantes-Rodrigues
RFRita Ferreira
Rita Ferreira
PBPaulo Brochado
Paulo Brochado
Paula A. OliveiraPaula A. Oliveira
Paula A. Oliveira

10 September 2017
Verified
Book Chapter
Closed access
PDF file
Paula A. OliveiraPaula A. Oliveira
Paula A. Oliveira
CNCarmen Nóbrega
Carmen Nóbrega
Rui M. Gil da CostaRui M. Gil da Costa
Rui M. Gil da Costa
RARegina Arantes-Rodrigues
Regina Arantes-Rodrigues

26 March 2014 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
Paula A. OliveiraPaula A. Oliveira
Paula A. Oliveira
RARegina Arantes-Rodrigues
Regina Arantes-Rodrigues
CNCarmen Nóbrega
Carmen Nóbrega
Urinary bladder cancer is a major human malignancy that afflicts millions of people worldwide every year. Urinary bladder cancer is usually superficial at presentation in 70 - 80% of patients. In these cases, a simple transurethral resection is adequate for removing the tumor. However, some patients experience recurrence or even tumor progression. In another 20 - 30% of patients, muscle-invasive carcinoma is diagnosed. Despite all the developments in this area, even today, the options for treatment of urinary bladder cancer remain inadequate. The search for the mechanisms involved in human urinary bladder cancer and for new and improved treatment methods has led to the development of many experimental models using laboratory animals over the past 40 years. In this review, the authors provide a concise overview of the animal models used to study urinary bladder cancer. Furthermore, the authors discuss their advantages and disadvantages with regard to the search for new therapeutic approaches. The use of urinary bladder cancer models for understanding the mechanisms involved in tumors' response to new treatments is an important step in the drug discovery process. However, the authors believe that it will be necessary to develop our knowledge and understanding of the molecular processes underlying urothelial chemical carcinogenesis for us to better evaluate the efficacy of novel therapeutics.

25 May 2018 in Transboundary and Emerging Diseases
Verified
Journal Article
Closed access
PDF file
RCRita Cruz
Rita Cruz
FEFernando Esteves
Fernando Esteves
CNCarmen Nóbrega
Carmen Nóbrega
CSCarla Santos
Carla Santos
AFAna S. Ferreira
Ana S. Ferreira
JMJoão Mesquita
João Mesquita